Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Gynaecology
  4. Gynaecology guidelines
  5. Back
  6. Guidelines A-Z (all Gynaecology guidelines)
  7. Elevated CA125: investigation & management, Gynaecology (1113)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Elevated CA125: investigation & management, Gynaecology (1113)

Warning

Objectives

To provide guidance on how to investigate women where a raised CA125 is found

Audience

Healthcare providers in primary and secondary care in Great Glasgow and Clyde (GGC)

CA125 is considered to be the best available marker for epithelial ovarian cancer.  

The widely accepted normal range of CA125 in GGC is 0-35 IU/ml.

Clinical Specificity of CA125

CA125 may be elevated in many physiological and pathological conditions, with gynaecological and non-gynaecological causes.  These conditions are summarised in the table below.

Table: list of conditions causing a raised CA125

CA125 Testing Recommendations

Primary Care

NICE recommends CA125 testing in primary care in women presenting with  1 of these following symptoms on a persistent or frequent basis, particularly if ≥ 12 x per month.

  • Persistent abdominal distension (‘bloating’)
  • Early satiety +/- loss of appetite
  • Pelvic or abdominal pain
  • Increased urinary urgency +/- frequency
  • Unexplained weight loss
  • Unexplained fatigue
  • Unexplained change of bowel habit
  • New onset of symptoms suggestive of IBS if 50 years

If CA125 is elevated >35 IU/ml, arrange an Ultrasound of the Pelvis – ideally Transvaginal Scan within 2 weeks.

Additionally if physical examination in primary care suggests ascites and or a pelvic or abdominal mass (which is not obviously uterine fibroids) they should be referred urgently for review in gynaecology and referral should not be delayed whilst waiting for CA125 result. 

Secondary Care

Abnormal Ultrasound Scan or imaging findings – premenopausal women

The Royal College of Obstetricians and Gynaecologists (RCOG) advises that a CA125 level is not routinely needed for the diagnosis of a simple cysts in premenopausal women. 

If germ cell origin tumours are suspected following imaging (e.g. women < 40yrs), αFP, βHCG and LDH are recommended in addition to CA125.

Please see GGC guidelines for further details.

Abnormal Ultrasound Scan or imaging findings – postmenopausal women

A CA125 level should be measured in all postmenopausal women with a cystic lesion of 1cm or more.  This should be used in conjunction with the USS findings to calculate the Risk of Malignancy Index Score (RMI).  Please see GGC guidelines for further details.

Normal pelvic ultrasound scan or imaging & Raised CA125

If a CA125 has been measured prior to imaging, a normal ultrasound can exclude ovarian cancer with a high degree of confidence. 

Postmenopausal ovaries will appear smaller and more homogenous compared to those found in pre-menopausal women. It is therefore common not to visualize the ovaries on ultrasound in a postmenopausal woman.  For completeness an abdominal examination and bimanual examination may be undertaken to assess for potential non pelvic masses.

In the presence of a normal pelvic ultrasound scan or imaging, there is no clear evidence to repeat a CA125 measurement.  However, extrapolating from ovarian cyst data, a rapidly rising CA125 is more likely to be associated with malignancy, therefore consider a repeat CA125 after 8 weeks to assess trend.  If significantly rising, further imaging by urgent CT scan of abdomen and pelvis should be arranged. 

If no gynaecological cause identified, patient should be referred back to GP to assess for other clinical causes of symptoms and investigate or refer as appropriate.

CA125 Flowchart

Flowchart of the steps for elevated CA125 investigations

Editorial Information

Last reviewed: 14/11/2023

Next review date: 31/10/2027

Author(s): Dr Jenifer Sassarini, Consultant O&G; Dr Claire Higgins Consultant O&G.

Approved By: Gynaecology Clinical Governance Group

Document Id: 1113

References

Ovarian cancer: recognition and initial management. NICE Guideline CG122 April 2011, Last review 2017.

Suspected cancer: recognition and referral, NICE guideline [NG12] Published: June 2015 Last updated: December 2021

Howe T, Sokolovsky N, Sayasneh A, Omar K, Tahmasebi F. Raised CA125–what we actually know... The Obstetrician & Gynaecologist2021;23:21–7.

RCOG Green-top Guideline No. 62. Management of suspected ovarian masses in premenopausal women. Dec 2011.

RCOG Green-top Guideline No. 34. Ovarian cysts in postmenopausal women. July 2016.

ACOG Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses, Obstetrics & Gynecology: November 2016 - Volume 128 - Issue 5 - p e210-e226

ACOG COMMITTEE OPINION Number 716 , September (Reaffirmed 2019) Committee on Gynecologic Practice Society of Gynecologic Oncology. The Role of the Obstetrician–Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk